NCT04989335 2023-11-28
Bisantrene Combination for Resistant AML
Sheba Medical Center
Phase 2 Unknown
Clinical Trials
17 trialsNCT05005299 2023-08-01
VICTORY
Melbourne Health
Phase 1 Unknown
NCT04217278 2023-05-10
COSI
University of Birmingham
Phase 2/3 Unknown
NCT05665075 2023-01-03
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia
Zhejiang University
Phase 1 Unknown
NCT05665114 2023-01-03
Natural Killer(NK) Cell Therapy in r/r AML
Zhejiang University
Phase 1 Unknown
NCT04112589 2022-03-14
A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
PETHEMA Foundation
Phase 1/2 Unknown
NCT05008575 2022-01-12
Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Xinqiao Hospital of Chongqing
Phase 1 Unknown
NCT04716114 2021-11-02
ALIVE
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Unknown
NCT03257241 2021-10-01
PALG-AML1/2016
Polish Adult Leukemia Group
Phase 3 Unknown
NCT05016063 2021-08-23
Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT04221971 2020-10-01
NK Cell Infusion for Patients With Acute Myeloid Leukemia
Peking University People's Hospital
Phase 1 Unknown
NCT02328950 2016-02-17
A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome
Fujian Medical University
Unknown
NCT02275663 2015-01-06
Azacytidine Plus FLAG for Relapsed or Refractory AML
King Fahad Medical City
Phase 2 Unknown
NCT02024308 2013-12-31
AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy
Changhai Hospital
Phase 4 Unknown
NCT00887042 2012-03-26
Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML
The Korean Society of Pediatric Hematology Oncology
Phase 1/2 Unknown
NCT00529880 2007-09-27
Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML
Cooperative Study Group A for Hematology
Phase 2 Unknown
NCT00199147 2005-10-26
Efficacy of G-CSF-Priming in Elderly AML Patients
Johann Wolfgang Goethe University Hospital
Phase 4 Unknown